Considerations for platform AAV affinity capture

Cell & Gene Therapy Insights 2024; 1(1), 145–148

DOI: 10.18609/cgti.2024.021

Published: 28 February
Innovator Insight
Jett Appel

From discovery to the clinic, as the quest to produce new, high-quality AAV molecules intensifies, an efficient and scalable platform purification process for many AAV serotypes is advantageous for both drug developers and CDMOs. In this poster, the considerations for evaluating a platform affinity capture step involving the industry leading POROSTM CaptureSelectTM AAV affinity resin for the purification of AAV vectors are explored.